Stockreport

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Serina Therapeutics, Inc.  (SER) 
PDF – Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targ [Read more]